Literature DB >> 3257202

Importance of fatty acid substituents of chemically synthesized lipid A-subunit analogs in the expression of immunopharmacological activity.

Y Kumazawa1, M Nakatsuka, H Takimoto, T Furuya, T Nagumo, A Yamamoto, Y Homma, K Inada, M Yoshida, M Kiso.   

Abstract

The immunopharmacological activities of chemically synthesized lipid A-subunit analogs, 4-O-phosphono-D-glucosamine derivatives carrying different N- and 3-O-linked acyl groups, were investigated. None of the synthetic compounds tested exhibited any detectable pyrogenicity at a dose of 10 micrograms/kg. Weaker lethal toxicity in galactosamine-sensitized mice was detected at 1 microgram per mouse for all the synthetic compounds except GLA-58. Among (RS) stereoisomers of 4-O-phosphono-D-glucosamine derivatives carrying a 3-O-tetradecanoyl (C14) group with different N-linked acyloxyacyl groups, i.e., 3-dodecanoyloxytetradecanoyl [C14-O-(C12)], 3-tetradecanoyloxytetradecanoyl [C14-O-(C14)], and 3-hexadecanoyloxytetradecanoyl [C14-O-(C16)] groups (termed GLA-57, GLA-27, and GLA-58, respectively), GLA-27 exhibited significant colony-stimulating factor-inducing and tumor necrosis factor-inducing activities, mitogenicity, polyclonal B-cell activation activity, macrophage activation, and adjuvanticity. The activities of GLA-57, which had an N-linked C14-O-(C12) group, were equivalent to or somewhat weaker than those of GLA-27 with a C14-O-(C14) group. Significant immunopharmacological activities were not observed for GLA-58, carrying a C14-O-(C16) group bound to the amino group. GLA-59, carrying 3-O-linked 3-hydroxytetradecanoyl (C14OH) and N-linked C14-O-(C14) groups, showed much higher activities than GLA-27, GLA-60, a compound which possesses the same fatty acid substituents as GLA-59 but with reversed binding sites, showed the strongest B-cell activation and adjuvant activities among the synthetic compounds. Among stereoisomers of GLA-59 and GLA-60 composed of fatty acid substituents with the (RR) and (SS) configuration, compounds with the (RR) configuration elicited stronger activities than the (SS) stereoisomers. The importance of fatty acid substituents, including stereospecificity for the expression of immunopharmacological activities of 4-O-phosphono-D-glucosamine derivatives, was demonstrated.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3257202      PMCID: PMC259249          DOI: 10.1128/iai.56.1.149-155.1988

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  20 in total

1.  Synthesis of the optically active 4-O-phosphono-D-glucosamine derivatives related to the nonreducing-sugar subunit of bacterial lipid A.

Authors:  M Kiso; S Tanaka; M Fujita; Y Fujishima; Y Ogawa; H Ishida; A Hasegawa
Journal:  Carbohydr Res       Date:  1987-04-15       Impact factor: 2.104

2.  Characterization of two membrane-associated glycolipids from an Escherichia coli mutant deficient in phosphatidylglycerol.

Authors:  M Nishijima; C R Raetz
Journal:  J Biol Chem       Date:  1981-10-25       Impact factor: 5.157

3.  Lipid A, the active part of bacterial endotoxins in inducing serum colony stimulating activity and proliferation of splenic granulocyte/macrophage progenitor cells.

Authors:  R N Apte; C Galanos; D H Pluznik
Journal:  J Cell Physiol       Date:  1976-01       Impact factor: 6.384

4.  Requirement of a properly acylated beta(1-6)-D-glucosamine disaccharide bisphosphate structure for efficient manifestation of full endotoxic and associated bioactivities of lipid A.

Authors:  I Takahashi; S Kotani; H Takada; M Tsujimoto; T Ogawa; T Shiba; S Kusumoto; M Yamamoto; A Hasegawa; M Kiso
Journal:  Infect Immun       Date:  1987-01       Impact factor: 3.441

5.  Biological activities of chemically synthesized analogues of the nonreducing sugar moiety of lipid A.

Authors:  M Matsuura; Y Kojima; J Y Homma; Y Kubota; A Yamamoto; M Kiso; A Hasegawa
Journal:  FEBS Lett       Date:  1984-02-27       Impact factor: 4.124

6.  Mitogenic and polyclonal B cell activation activities of synthetic lipid A analogues.

Authors:  Y Kumazawa; M Matsuura; Y Nakatsuru-Watanabe; M Fukumoto; C Nishimura; J Y Homma; M Inage; S Kusumoto; T Shiba
Journal:  Eur J Immunol       Date:  1984-02       Impact factor: 5.532

7.  Biological activity of synthetic heptaacyl lipid A representing a component of Salmonella minnesota R595 lipid A.

Authors:  C Galanos; O Lüderitz; M Freudenberg; L Brade; U Schade; E T Rietschel; S Kusumoto; T Shiba
Journal:  Eur J Biochem       Date:  1986-10-01

8.  Effect of stereospecificity of chemically synthesized lipid A-subunit analogues GLA-27 and GLA-40 on the expression of immunopharmacological activities.

Authors:  Y Kumazawa; S Ikeda; H Takimoto; C Nishimura; M Nakatsuka; J Y Homma; A Yamamoto; M Kiso; A Hasegawa
Journal:  Eur J Immunol       Date:  1987-05       Impact factor: 5.532

9.  Molecular requirements for B-lymphocyte activation by Escherichia coli lipopolysaccharide.

Authors:  C R Raetz; S Purcell; K Takayama
Journal:  Proc Natl Acad Sci U S A       Date:  1983-08       Impact factor: 11.205

10.  Fatty acyl derivatives of glucosamine 1-phosphate in Escherichia coli and their relation to lipid A. Complete structure of A diacyl GlcN-1-P found in a phosphatidylglycerol-deficient mutant.

Authors:  K Takayama; N Qureshi; P Mascagni; M A Nashed; L Anderson; C R Raetz
Journal:  J Biol Chem       Date:  1983-06-25       Impact factor: 5.157

View more
  17 in total

1.  SDZ MRL 953, a novel immunostimulatory monosaccharidic lipid A analog with an improved therapeutic window in experimental sepsis.

Authors:  C Lam; E Schütze; J Hildebrandt; H Aschauer; E Liehl; I Macher; P Stütz
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  Immunopharmacological activities of 2-keto-3-deoxyoctonic acid-(alpha 2----6)-linked 4-O-phosphono-D-glucosamine derivatives carrying N- and 3-O-acyl substituents.

Authors:  Y Kumazawa; M Matsuura; J Y Homma; T Furuya; H Takimoto; K Inagaki; T Nagumo; M Kiso; A Hasegawa
Journal:  Infect Immun       Date:  1989-06       Impact factor: 3.441

3.  Activity of monosaccharide lipid A analogues in human monocytic cells as agonists or antagonists of bacterial lipopolysaccharide.

Authors:  M Matsuura; M Kiso; A Hasegawa
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

4.  Antimetastatic effect of endogenous tumor necrosis factor induced by the treatment of recombinant interferon gamma followed by an analogue (GLA-60) to synthetic lipid A subunit.

Authors:  I Saiki; H Maeda; J Murata; N Yamamoto; M Kiso; A Hasegawa; I Azuma
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

5.  Inflammasome-mediated secretion of IL-1β in human monocytes through TLR2 activation; modulation by dietary fatty acids.

Authors:  Ryan G Snodgrass; Shurong Huang; Il-Whan Choi; John C Rutledge; Daniel H Hwang
Journal:  J Immunol       Date:  2013-09-16       Impact factor: 5.422

6.  Relationship of structure and biological activity of monosaccharide lipid A analogues to induction of nitric oxide production by murine macrophage RAW264.7 cells.

Authors:  K Funatogawa; M Matsuura; M Nakano; M Kiso; A Hasegawa
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

7.  Low biological activity of Helicobacter pylori lipopolysaccharide.

Authors:  A Muotiala; I M Helander; L Pyhälä; T U Kosunen; A P Moran
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

8.  Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity.

Authors:  S Barnoy; K I Jeong; R F Helm; A E Suvarnapunya; R T Ranallo; S Tzipori; M M Venkatesan
Journal:  Vaccine       Date:  2009-11-20       Impact factor: 3.641

9.  Enhancement of immunoglobulin G responses in mice against hepatitis B virus surface antigen, influenza virus hemagglutinin vaccine, and tetanus toxoid by 6-O-acylated muramyl dipeptides.

Authors:  T Furuya; Y Kumazawa; H Takimoto; T Nagumo; M Watanabe; C Aizawa; M Kiso; A Hasegawa; K Nomoto
Journal:  Infect Immun       Date:  1989-06       Impact factor: 3.441

Review 10.  Molecular adjuvants and immunomodulators: new approaches to immunization.

Authors:  A G Johnson
Journal:  Clin Microbiol Rev       Date:  1994-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.